Ameriprise’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Ameriprise’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-31,732	Closed	-$582K	–	3874
2020 Q3	$582K	Buy	+31,732	New	+$533K	﹤0.01%	3192

Other funds holding CBMG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise's CBMG Position: Q4 2020 in Review

Ameriprise sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2020, closing a stake of 31,732 shares — an estimated $582K sold.

Ameriprise first reported a position in CBMG in Q3 2020 and held it in 1 quarter. The position peaked at $582K in Q3 2020. 67 funds tracked by Wall St. Rank hold CBMG as of Q4 2020.

Ameriprise reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2020 after selling out during the quarter.
Ameriprise sold 31,732 Cellular Biomedicine Group, Inc. shares in Q4 2020, an estimated $582K.
Ameriprise first reported a position in Cellular Biomedicine Group, Inc. in Q3 2020 and held it in 1 quarter.
Ameriprise's Cellular Biomedicine Group, Inc. position peaked at $582K in Q3 2020.
67 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2020.

Based on Ameriprise's 13F filing for Q4 2020, filed 12 Feb 2021.